ENvue Medical's Total Assets for the quarter that ended in Mar. 2026 was $39.87 Mil.
During the past 12 months, ENvue Medical's average Total Assets Growth Rate was -13.50% per year.
During the past 3 years, the average Total Assets Growth Rate was 126.70% per year.
During the past 5 years, the average Total Assets Growth Rate was 83.40% per year.
During the past 10 years, the average Total Assets Growth Rate was 43.90% per year.
During the past 13 years, ENvue Medical's highest 3-Year average Total Assets Growth Rate was 126.70%. The lowest was -13.40%. And the median was 25.95%.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
ENvue Medical's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
ENvue Medical Total Assets Related Terms
ENvue Medical Total Assets Historical Data
* Premium members only.
The historical data trend for ENvue Medical's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
ENvue Medical's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ENvue Medical (FEED) has a Total Assets of $39.87 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on ENvue Medical and its competitors.
Is ENvue Medical's Total Assets too high?
ENvue Medical's current Total Assets is $39.87 Mil. Overall, ENvue Medical has a GF Score™ of 34/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ENvue Medical's Total Assets compare to BTCY and LUDG?
ENvue Medical's Total Assets of $39.87 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Medical Devices & Instruments company?
A good Total Assets depends on the Medical Devices & Instruments industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on ENvue Medical and its competitors. ENvue Medical's current Total Assets is $39.87 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ENvue Medical stock overvalued right now?
Based on GuruFocus' analysis, ENvue Medical (FEED) is currently considered Possible Value Trap. The stock's GF Value™ is $5.13, compared to a current price of $0.52 — trading 89.8% below its estimated fair value. The current Total Assets is $39.87 Mil. ENvue Medical's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For ENvue Medical (FEED), the current Total Assets is $39.87 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ENvue Medical (FEED) Overvalued in 2026?
Based on GuruFocus' analysis, ENvue Medical stock appears to be undervalued.
The current stock price of $0.52 is trading 89.8% below its estimated GF Value™ of $5.13.
GuruFocus considers ENvue Medical to be Possible Value Trap.
Key valuation signals for FEED:
Total Assets: $39.87 Mil
GF Value™: $5.13 vs. price of $0.52 (89.8% below fair value)
No single metric tells the full story. See the FEED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ENvue Medical Inc develops medical devices for enhanced navigation in clinical procedures. The company provides personalized navigation technology to assist clinicians in placing feeding tubes safely and efficiently. Its ENvue system uses smart feeding tubes with sensors, body mapping, and continuous visual guidance to confirm accurate positioning and reduce complications like lung misplacement. The company conducted the business through two primary operating segments: NanoVibronix and ENvue. The firm generates the majority of its revenue from NanoVibronix, which derives revenues from selling its products directly to patients as well as through distributor agreements. ENvue derives revenues from selling its Systems and Nasoenteral tubes.
34GF Score
Get the complete analysis for FEED
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FEED has been successfully added to your 
